Denali Therapeutics Inc. Revenue from Related Parties
Denali Therapeutics Inc. (DNLI) reported Revenue from Related Parties of $3.20 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-27.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2023-02-27
- Denali Therapeutics Inc. revenue from related parties for the quarter ending 2022-12-31 was $300.00K, a 75.00% decline year-over-year.
- Denali Therapeutics Inc. revenue from related parties for the quarter ending 2022-09-30 was $200.00K, a 77.78% decline year-over-year.
- Denali Therapeutics Inc. revenue from related parties for the quarter ending 2022-06-30 was $500.00K, a 37.50% decline year-over-year.
- Denali Therapeutics Inc. revenue from related parties for the quarter ending 2022-03-31 was $2.20M, a 144.44% increase year-over-year.
- Denali Therapeutics Inc. revenue from related parties for fiscal 2022 was $3.20M, a 13.51% decline from fiscal 2021.
- Denali Therapeutics Inc. revenue from related parties for fiscal 2021 was $3.70M, a 98.80% decline from fiscal 2020.
- Denali Therapeutics Inc. revenue from related parties for fiscal 2020 was $307.40M.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 9 month | Revenue from Related Parties 12 month | Revenue from Related Parties 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $500.00K derived: sum of 2 quarters · filed 2023-02-27 | $1.00M derived: sum of 3 quarters · filed 2023-02-27 | $3.20M 10-K · filed 2023-02-27 | |
| 2022-09-30 | $200.00K 10-Q · filed 2022-11-03 | $700.00K derived: sum of 2 quarters · filed 2022-11-03 | $2.90M 10-Q · filed 2022-11-03 | $4.10M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2022-06-30 | $500.00K 10-Q · filed 2022-08-08 | $2.70M 10-Q · filed 2022-08-08 | $3.90M derived: sum of 3 quarters · filed 2023-02-27 | $4.80M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2022-03-31 | $2.20M 10-Q · filed 2022-05-05 | $3.40M derived: sum of 2 quarters · filed 2023-02-27 | $4.30M derived: sum of 3 quarters · filed 2023-02-27 | $5.10M derived: sum of 4 quarters · filed 2023-02-27 | |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $2.10M derived: sum of 2 quarters · filed 2023-02-27 | $2.90M derived: sum of 3 quarters · filed 2023-02-27 | $3.70M 10-K · filed 2023-02-27 | $3.74M 10-K · filed 2022-02-28 |
| 2021-09-30 | $900.00K 10-Q · filed 2022-11-03 | $1.70M derived: sum of 2 quarters · filed 2022-11-03 | $2.50M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $800.00K 10-Q · filed 2022-08-08 | $1.70M 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $900.00K 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $307.40M 10-K · filed 2023-02-27 | $307.44M 10-K · filed 2021-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |